An issue of dependence: Implications from the Aliskiren in the evaluation of proteinuria in diabetes (AVOID) trial

Journal of Clinical Hypertension

Volumn 11, Issue 2, 2009, Pages 89-93

  Riche, Daniel M ^a,b   Minor, Deborah S ^a,b   Holdiness, Amber S ^a   East, Honey E ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MEDICAL RESEARCH; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; TREATMENT OUTCOME;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FUMARATES; HUMANS; HYPERTENSION; PROTEINURIA; TREATMENT OUTCOME;

EID: 60549100908     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00069.x     Document Type: Article

References (15)

1. Parving H-H, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
2. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31(suppl 1):S12-S54.
3. Kunz R, Wolbers M, Glass T, et al. The COOPERATE trial: A letter of concern. Lancet. 2008;371:1575-1576.
4. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
5. Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis. Diabet Med. 2007;24:486-493.
6. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. Br Med J. 2000;321:1440-1444.
7. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
8. Sarangapani R, Ebling W, Bush CA, et al. Clinical assessment and modeling interpretation of the differential effects of direct renin inhibitor on renal disease progression: Analysis of AVOID study. J Clin Hypertens. 2008;10(5):A33.
9. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE Substudy. Hypertension. 2001;38:E28-E32.
10. Smith DH, Cramer MJ, Neutel JM, et al. Comparison of telmisartan versus losartan: Meta-analysis of titration-to-response studies. Blood Press Monit. 2003;8(3):111-117.
11. Sica D, Anderson K, Byung-Hee O, et al. Effects of aliskiren on blood pressure and plasma renin activity persist after stopping treatment in patients with hypertension. J Clin Hypertens. 2008;10(5):A34-A35.
12. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
13. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
14. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
15. Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007;50:2398-2404.